Effect of different doses of Esticketamine combined with propofol in painless endoscopy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062547

Enrollment

Unknown

Registered

2022-08-11

Start date

2022-08-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive endoscopy

Interventions

C:propofol 2mg/kg I.V.?

E:propofol 2mg/kg and esketamine 0.5mg/kg I.V

S:propofol 2mg/kg and sufentanil 0.1µg/kg I.V.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients receiving total intravenous anesthesia; 2. Patients with complete clinical records; 3. ASA grade I-II.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of allergy to the test drug; 2. Patients with heart, lung, liver, kidney, blood, and other important systemic diseases; 3. Patients with communication disorders or cognitive disorders; 4. Patients with symptoms of respiratory infection.

Design outcomes

Primary

Measure	Time frame
Heart Rate(HR);blood pressure(BP);oxygen saturation(SpO2);	—

Countries

China

Contacts

Public ContactZheng Longbin

272425852@qq.com+86 18061750597

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026